Izeltabart

Izeltabart (MGA021) is a humanized IgG1 monoclonal antibody targeting ADAM9, which can be used as an ADC Antibody to synthesize the ADC molecule IMGC936 (Izeltabart Tapatansine) . Izeltabart can be used in the study of cancer[1].

Product Specifications

CAS Number

[2642078-60-0]

Product Name Alternative

IMGC-936 antibody; MGA021

UNSPSC

12352203

Target

ADC Antibody; MMP

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/izeltabart.html

Purity

99.91

Solubility

10 mM in DMSO

Smiles

[Izeltabart]

Molecular Weight

(147.4 kDa)

References & Citations

[1]Juniper A Scribner, et al. Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Mol Cancer Ther. 2022 Jul 5;21 (7) :1047-1059.